VR Logo

Karuna Therapeutics Inc. (KRTX) download report


Healthcare | Biotechnology & Pharma Research

Karuna Therapeutics Inc. (KRTX) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions.

IPO Date: 28-Jun-2019

CEO, Pres & Chairman: Dr. Steven M. Paul M.D.

Co-Founder & COO: Dr. Andrew Craig Miller

Listing: NASDAQ: KRTX

Country: United States

Headquarters: Boston, MA

Website: https://www.karunatx.com

Key Facts

Market cap: $3,734.74 Mln

Revenue (TTM): $36.96 Mln

Earnings (TTM): $-171.53 Mln

Cash: $443.19 Mln

Total Debt: $6.98 Mln

Insider's Holding: 7.24%

Liquidity: Low

52 Week range: $92.26 - 161.98

Shares outstanding: 29,882,700

5 Years Aggregate:

  • CFO: $-221.06 Mln
  • EBITDA: $-276.29 Mln
  • Net Profit: $-279.86 Mln

Stock Performance

Time Period Karuna Therapeutics (KRTX) S&P BSE Sensex S&P Small-Cap 600
YTD-3.74-9.18-18.78
1 month17.29-4.78-8.00
3 months-0.54-9.66-13.65
1 Year10.620.81-17.19
3 Years84.6810.336.10
5 Years--11.345.87
10 Years--11.749.84
As on 01-Jul-2022
Year Karuna Therapeutics (KRTX) S&P Small-Cap 600 S&P BSE Sensex
202128.9525.2721.99
202034.849.5715.75